In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its ...

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with ...

The market worth was recorded at $3.16 billion in 2024 and is projected to escalate to $3.68 billion in 2025, unfolding at a robust compound annual growth rate CAGR of 16.1%. The proficient growth in ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...

Myrio Therapeutics Pty Ltd. is set to advance lead product PHOX2B PC-CAR T (PHOX2B peptide-centric chimeric antigen receptor autologous T cells) into clinical trials for relapsed neuroblastoma ...

The firm is developing the PHOX2B-targeted cell therapy, which has shown promise in preclinical xenograft models, with CHOP researchers.

About a month ago, I woke up without hearing in my left ear. I initially suspected a wax blockage or a blocked eustachian ...

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new ...

New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted ...

Northwestern University’s International Institute for Nanotechnology (IIN) has announced the recipients of the 2025 ...